Mike Goguen & Rob Williamson: “The Best Companies Start in the Worst Times”
What you’ll learn
- Why capital efficiency, not the funding climate, separates the biotechs that survive a downturn
- What Goguen means by “beware the kindness of strangers”, and how founders minimize dependence
- How to spot real AI in drug discovery versus window dressing
- Why an early-stage biotech can’t win the AI salary war, and what recruits talent anyway
- Whether we’re in an AI bubble, and how to exploit one without being blinded by it
Mike Goguen is the founder and managing partner of Two Bear Capital, investing at the intersection of tech and life sciences. Before founding Two Bear in 2019, Mike spent 20 years as a general partner at Sequoia Capital (1996-2016), investing mostly in tech with a lean toward biotech. Two Bear has ~25 portfolio companies across two main funds, with about a third focused on deep biotech in oncology and neuro.
Rob Williamson is the founder and CEO of Traverse Therapeutics, a stealth AI biotech developing a platform for targeted drug delivery across the blood-brain barrier. With 35+ years in drug development, Rob has brought multiple drugs to market. Former BCG partner, economist by training, he founded his first biotech (a genomics company) in 1999. He also serves on the board of a public radio-oncology company.
In Today’s Episode We Discuss:
- “I’ve Called It My Vow of Poverty” — Why Biotech Over Tech
- Minimizing Investor Dependence
- The Best Companies Are Founded in the Worst Times
- First-Time Founders vs Experienced Operators — What VCs Want
- Product-Market Fit in Biotech — Understanding Pharma’s Pain Points
- M&A Is Slower Than Expected — Why Deals Are Stalling
- The AI Revolution in Drug Discovery — What’s Real vs Hype
- AlphaFold, Digital Twins, and the In Silico-In Vitro Loop
- “Where’s the Beef?” — Spotting Real AI vs Window Dressing
- Biotech Can’t Compete for AI Talent — Half a Million Out of School
- Are We in an AI Bubble? Lessons from Multiple Crashes
- Quantum AI — The Revolution After the Revolution
Resources:
some of the best companies were founded during some of the worst times. And it’s almost Darwinian because when the times are really easy ... lots of money getting thrown at a category and it’s kind of hyped it’s the quality bar sort of goes down a little bit
Key takeaways
- The best companies start in the worst times. Easy money lowers the quality bar. Downturns force the discipline that makes a company durable.
- Capital efficiency is the core screen. Goguen backs founders who reach milestones on less, so a bad environment can’t sink them.
- Beware the kindness of strangers. Every partner and future investor is a dependence, and the best models minimize it.
- First-time science founders are a feature, not a risk. Two Bear likes domain experts with a novel idea over a polished startup résumé.
- Biotech’s product-market fit is pharma. Understand what pharma will want as partner, acquirer, or customer before you build.
- Time kills catalyzed deals. Once M&A is in motion, committed management on both sides is what closes it.
- “Where’s the beef?” Everyone claims AI. The test is a real before-and-after difference one level below the buzzwords.
- The AI talent war is real. Pre-seed biotech can’t match half-million-dollar offers, so mission and belief become the recruiting edge.
- Know the bubble, don’t depend on it. Exploit a frothy round if it comes, but build so you’re fine when sentiment reverses.
Key Questions, Answered
How should founders think about capital in a tough funding environment?
the capital efficiency of some of the companies we back is ... a core consideration. And we’re always looking for founders who do things a little more cleverly ... on the amount of capital required to get to milestones
Mike Goguen: capital efficiency is the core screen. Founders who hit milestones on less money survive environments that sink the rest.
What does ‘beware the kindness of strangers’ mean for a startup?
everybody is a stranger other than your founders and the folks in the company ... you’re counting on partners to do things. You’re also counting on new investors down the road to invest. Those are strangers. So point has always been just try to minimize that.
The only people who aren’t strangers are your founders and team. Every partner and future investor is a dependence to minimize.
Do venture investors prefer experienced founders or first-timers?
they can be first-time founders, so I actually like first-time founders. Science founders never started a company before.
Two Bear backs first-time science founders. Domain conviction and a novel idea beat a prior startup résumé.
What is product-market fit for a biotech company?
before you start a new biotech company ... understanding that pharma companies are likely the partners and or acquirers and or ... your customers in some sense, really understanding what they likely are to be interested in and not.
Biotech’s version of product-market fit: know what pharma will want as partner, acquirer, or customer before you build.
Why have biotech M&A deals been slower than expected?
what kills a transaction once it’s catalyzed ... is really time. And it takes a strong management team ... on both sides to drive a deal.
Rob Williamson: once a deal is catalyzed, time is what kills it. It takes committed management on both sides to push it through.
What actually changed to make AI matter in drug discovery?
in the biotech world you were getting better and better instrumentation ... we were getting more visibility into biology that manifested as data ... And then over here you had what started out as the large language models.
Better instrumentation turned biology into data just as large language models matured. The two streams crossing is the real breakthrough.
What kind of AI biotech is worth backing?
a lot of the purely in silico AI drug design companies ... invent molecules from whole cloth. At least in our company so far, we’ve got a lot more mileage from they still have a big biological piece.
Goguen is wary of pure in-silico drug design. His firm gets more mileage from AI paired with a real wet-lab biology loop.
How do you tell real AI from hype?
the buzzwords are all getting thrown around and ... folks are trying to do as much ... window dressing as they can to make themselves look relevant and hot. So, you have to dig that next level down.
Everyone claims AI. The test is ‘where’s the beef’: dig one level down to a real before-and-after difference.
Can an early-stage biotech compete for AI talent?
they’re getting offered half a million comp right out to go work for ... the LLM platform companies. And I’m a biotech, you know, that’s really pre-seed ... I cannot attract these people.
Rob Williamson: LLM platforms offer new grads half a million. A pre-seed biotech can’t match it, so belief in the mission becomes the lever.
Are we in an AI bubble, and what should investors do?
you have to be aware of when you’re in a bubble and exploit it if possible ... you just have to be conscious of ... you can’t get blinded by it. You have to recognize that it could change in a split second
Recognize the bubble and use it, but never depend on it. Build so you’re fine when the wind blows the other way.
Resources
- Two Bear Capital Mike Goguen’s venture firm (founded 2019), investing at the intersection of tech and life sciences.
- Sequoia Capital Where Goguen spent 20 years as a General Partner (1996–2016) before founding Two Bear.
- AlphaFold (Google DeepMind) The protein-structure-prediction system Goguen cites as a computational-biology breakthrough.
- Traverse Therapeutics — Rob Williamson Williamson’s stealth AI biotech developing targeted drug delivery across the blood-brain barrier.
Need the life-sciences signal but short on time?
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.
